Phase 0 Trial of LB100, A Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Trial Profile

Phase 0 Trial of LB100, A Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma

Not yet recruiting
Phase of Trial: Phase 0

Latest Information Update: 29 Jan 2018

At a glance

  • Drugs LB 100 (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Pharmacokinetics
  • Most Recent Events

    • 19 Jan 2018 Trial focus and primary end point were changed from pharmacodynamics to pharmacokinetics. The secondary end points were removed from profile.
    • 31 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top